Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Harm reduction with e-cigarettes

If not stop, then at least minimize the damage

    • Congress Reports
    • General Internal Medicine
    • Oncology
    • Pneumology
    • Prevention and health care
    • RX
    • Studies
  • 7 minute read

Worldwide, around 30-40% of cardiovascular diseases are attributable to smoking. This figure is around 80% for cancer cases and 63% for COPD cases. Around half of healthcare costs can be linked to cigarette consumption. A complete ban seems unrealistic at present, but limiting the damage by using substitutes such as e-cigarettes could make a big difference.

Quitting smoking is the best way to limit damage to your health. However, only 30-40% succeed in quitting smoking, including those who take advantage of psychological and pharmacological support. Harm reduction is an important tool for those who are unable to stop smoking.

In 2018, the costs associated with smoking cigarettes amounted to around 600 billion dollars, explained Prof. Dr. Andrzej Fal, Director of the Institute of Medical Science at the Cardinal Wyszyński University (UKSW) and Head of the Department of Allergy, Lung Diseases and Internal Diseases at the Central Clinical Hospital of the Ministry of the Interior in Warsaw and President of the Polish Public Health Society, at the 6th Polish Public Health Forum in Warsawth Summit Tobacco Harm Reduction in Athens [1]. 240 billion dollars are spent on healthcare, 184 billion dollars correspond to the loss of productivity due to smoking-related illnesses and health impairments. A further 180 billion dollars is accounted for by productivity losses due to premature deaths in the working population caused by smoking. And finally, there are 7 billion dollars in losses for those who die prematurely even though they are only passive smokers. “This must be emphasized: Smoking cigarettes is the only habit where the smoker does something – namely exhale – and someone else gets sick by inhaling.”

“Road Map” over 12 years

Some countries and governments have learned their lessons from this, as Prof. Fal explained, citing the example of New Zealand: The government there had spent 12 years preparing for the January 1, 2024 deadline. On the one hand there was an awareness campaign, on the other a policy of prohibition and control mechanisms for public health (Fig. 1). “There was a timetable for increasing the cigarette tax – ten times in 12 years! Every smoker knew that cigarettes would still be 10% more expensive next year than this year. So it was a kind of stress incentive and helped those who wanted to quit.”

From his own experience and work in Poland, Prof. Fal gave some recommendations on how to proceed efficiently in order to reduce the number of cigarette smokers and tobacco addicts in a structured way in the future:

1. priority prevention (social and economic policy measures that have an impact on health)
Establishment of at least one prevention clinic in each district/county:

  • They should be managed by trained specialists.
  • The clinics should be accessible without referral.
  • They should be responsible for regional health prevention, programs (including schools) and smoking cessation, information campaigns – these campaigns should be uniform nationwide and less geared to regional needs.
  • The coherence of the message should come first.

2. primary prevention

  • Regulating the market by sensibly reducing availability, especially in the fast-selling areas (e.g. petrol stations). Ban the exposure of products at the point of sale.
  • Radical but gradual increase in excise duties (and thus the price) for cigarettes as the most harmful products for smokers and their environment.

3. secondary prevention

Establish at least one prevention clinic in each district/county:

  • For the reasons already mentioned under “1. Priority prevention”, but also, in the context of secondary prevention, to enable unrestricted access to anti-smoking therapy, nicotine replacement, pharmacotherapy and harm-reduction products.

4. tertiary prevention

Revision of the legislation:

  • All products associated with smoking and nicotine should be subject to the same rules on sales and marketing restrictions.
  • In the group thus defined, structure the consumption tax according to the motto “less damage, less tax”.

Do e-cigarettes suppress smoking cessation?

The extent to which e-cigarettes can help smokers who want to quit smoking normal cigarettes has often been the subject of heated debate since their market launch. A study group began systematically evaluating findings and evidence on this topic in 2023. Their initial preliminary results, presented by Dr. Renee O’Leary, Centre for the Acceleration of Harm Reduction, University of Catania, Italy, included data from five systematic reviews since 2021, which examined a total of 21 randomized controlled trials (RCTs) and 18 longitudinal cohort studies [2]. The scientists investigated two areas with regard to smoking cessation and the significance of e-cigarettes: firstly, the cessation rate and secondly, the comparative effectiveness.

With regard to people who had switched from cigarettes to e-cigarettes, 44% were still abstaining from traditional cigarettes six months after the switch. At the lower end, the rate was 14% after 12 months, but only in relation to a group that had no intention of quitting traditional smoking. The drop-out in this cohort was spontaneous. Overall, the success rate for quitting is around 10%. “That’s why we need harm reduction, because even those who try don’t succeed in quitting smoking,” Dr. O’Leary said.

On the other hand, the meta-analysis of the cohort studies revealed no significant differences in cessation rates between the groups. No improvement, but no disadvantage either. Dr. O’Leary therefore disagrees with the assertion that e-cigarettes suppress smoking cessation: “At worst, they make no difference.” She attributes the different results between the cohort studies and the RCTs to the methodology. “In the RCTs, you are in the laboratory, the subjects are aware of the situation, they think about what they are doing and consider changing something about their behavior.” In a cohort study, on the other hand, the doctors do not intervene.

Putting an end to tobacco addiction with ENDS

A large amount of positive data for the comparative effectiveness of e-cigarettes (ENDS – Electronic Nicotine Delivery System) could be read from the RCTs, the expert explained. When looking at nicotine ENDS, these were significantly more effective by a median of 161% compared to behavioral therapy or no support. Even at the lowest end of the statistical comparison, ENDS were 44% more effective (44%-374%) than no support or behavioral therapy alone.

With regard to nicotine replacement therapy (NRT), two systematic reviews have found that ENDS are 65% more effective than NRTs in smoking cessation. A third review showed no significant difference in efficacy. The range here was from 3% less effective to 109% more effective. Another study looked at ENDS compared to any type of therapy. Here, ENDS were more effective by a median of 55%.

Is science too unscientific?

“In 2016, we conducted a study among healthcare professionals in Greece and found that the vast majority (85.2%) of this group, i.e. doctors, physicians and nurses, identified the contribution of nicotine to smoking-related atherosclerosis as important, very important or extremely important,” explained Dr. Konstantinos Farsalinos, Department of Public and Community Health, University of Patras [3]. The results for lung diseases and cancer would be similar. According to Dr. Farsalinos, the vast majority of healthcare professionals thus represent a position that has long been proven wrong.

The situation is even worse in the general population: In a 2017 study of more than 4,000 people from the greater Athens area, only 4.6% of active smokers reported that they thought e-cigarettes were significantly less harmful than tobacco cigarettes. In contrast, almost 40% said they were at least as harmful or even more harmful than tobacco cigarettes.

So it seems that something is going wrong in communication, which is resulting in widespread misinformation. The expert sees the reasons for this in the problematic attitude of politically controlled tobacco control, which is mainly dogmatic, ideologically based and tries to find evidence to support the ideology. “So it’s the exact opposite of what we do in science: In science, we collect data and evidence and then draw our conclusions and recommendations.” A large part of the anti-tobacco movement, on the other hand, acts in exactly the opposite way: “They make decisions and recommendations and then try to find evidence to support their predetermined conclusions. It’s a constant cherry-picking and deliberate misinterpretation of evidence.”

Dr. Farsalinos cited the EVALI case from the USA as an example of his thesis. EVALI (“E-cigarettes or Vaping Use-associated Lung Injury”) is an acute lung injury which, according to initial assessments, was caused by e-cigarettes. It later turned out that the trigger was most likely illegal liquids that had been diluted with vitamin E acetate. “The CDC and FDA accepted that they were caused by illegal marijuana products, but the name still enshrined e-cigarettes and vaping and never changed,” Dr. Farsalino’s interpretation said.

“All this data tells us that ENDS should be promoted because they have been shown in RCTs to be more effective than other treatments,” Dr. O’Leary concluded. “Also, we’d like to think that a good part of the effect of ENDS is behavioral substitution, but that doesn’t seem to be the case. In two of the systematic reviews, nicotine-containing ENDS were 75% more effective than nicotine-free ENDS, meaning that behavioral support appears to be present to some degree, but not as strong as we would like.”

The scientist also referred to a recent study in which the test subjects had to be abstinent for six months without interruption, and abstinence also had to be proven biochemically. ENDS were 77% more effective in this study than any other treatment investigated. “That’s a big improvement. And with smoking cessation, we need every kind of improvement we can get. If ENDS offer that route, then they need to be taken seriously as an option.”

Take-Home Messages

  • Prevention is the most effective way to invest in future health.
  • Lifestyle changes, reduction of behavioral risk factors and harm reduction can reduce the burden of non-communicable diseases (NCDs).
  • NCDs are responsible for more than 90% of premature deaths and more than 60% of curative medical costs in highly developed countries.
  • In order to stop the smoking pandemic and its financial and health effects, it is necessary: 1. increase funding for primary prevention (lifelong education) and 2. introduction of the “less damage, less tax” scheme
  • 44% of smokers who switched from cigarettes to e-cigarettes remained abstinent from traditional cigarettes 6 months after the switch.
  • ENDS have been shown to be more effective than NRTs for smoking cessation.

Sources:

  1. Fal A: On our way to a smoke free world – a common point of view of public health and economy. Keynote Speech,6th Summit Tobacco Harm Reduction, Athens, 25.09.2023.
  2. O’Leary R: At the Top of the Evidence Pyramid – Clinical Evidence on the Effectiveness of E-Cigarettes for Tobacco Cigarette Cessation,6th Summit Tobacco Harm Reduction, Athens, 26.09.2023.
  3. Farsalinos K: Tobacco Control in the21st century from a socio-ethical perspective. Keynote Speech,6th Summit Tobacco Harm Reduction, Athens, 26.09.2023.
  4. Ministry of Health: Proposals for a Smokefree Aotearoa 2025 Action Plan: Discussion document. Wellington: Ministry of Health 2021.

Congress:6th Summit Tobacco Harm Reduction

FAMILY PHYSICIAN PRACTICE 2023; 18(11): 42-44

Autoren
  • Jens Dehn
Publikation
  • HAUSARZT PRAXIS
Related Topics
  • E-cigarettes
  • harm reduction
  • Nicotine replacement
  • Smoking
  • Smoking cessation
  • Tobacco
Previous Article
  • GLP-1 agonists continue to gain ground

Semaglutide in patients with obesity and heart failure

  • Cardiology
  • Congress Reports
  • Endocrinology and Diabetology
  • General Internal Medicine
  • RX
  • Studies
View Post
Next Article
  • RESEARCH

Development of a retina-like biochip

  • Neurology
  • Ophthalmology
  • RX
View Post
You May Also Like
View Post
  • 7 min
  • Journal Club

Management of axial spondyloarthritis

    • Education
    • General Internal Medicine
    • Geriatrics
    • Rheumatology
    • RX
    • Sports Medicine
    • Studies
View Post
  • 5 min
  • Multiple myeloma

DREAMM-7: Belamaf plus bortezomib and dexamethasone outperforms comparator therapy

    • Education
    • Hematology
    • Oncology
    • RX
    • Studies
View Post
  • 5 min
  • COPD

Better outcomes through patient education and integrated care

    • Education
    • General Internal Medicine
    • Pneumology
    • RX
View Post
  • 6 min
  • Interview

“Wearables are increasingly accepted as an aid”

    • Education
    • Endocrinology and Diabetology
    • Interviews
    • Prevention and health care
    • RX
View Post
  • 4 min
  • Exogenous allergic alveolitis

Recommendations for therapy for the first time

    • Congress Reports
    • General Internal Medicine
    • Pneumology
    • RX
View Post
  • 3 min
  • Kidney cancer

Urine test could halve the number of postoperative kidney cancer scans

    • Congress Reports
    • Nephrology
    • Oncology
    • Prevention and health care
    • RX
    • Studies
View Post
  • 6 min
  • Evidence, potential and limits

Phytotherapy for rheumatoid arthritis

    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Pharmacology and toxicology
    • Phytotherapy
    • Rheumatology
    • RX
    • Studies
View Post
  • 4 min
  • Esophageal stenosis and atresia

Magnet enables anastomosis and recanalization

    • Gastroenterology and Hepatology
    • General Internal Medicine
    • ORL
    • RX
    • Surgery
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.